Form 8-K - Current report:
SEC Accession No. 0001549595-25-000014
Filing Date
2025-01-28
Accepted
2025-01-28 16:03:42
Documents
14
Period of Report
2025-01-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20250128.htm   iXBRL 8-K 28080
2 EX-99.1 nrix-20250128xexx991.htm EX-99.1 99633
  Complete submission text file 0001549595-25-000014.txt   276509

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20250128.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20250128_lab.xml EX-101.LAB 24350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20250128_pre.xml EX-101.PRE 14116
16 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20250128_htm.xml XML 3016
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 25564092
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)